Bitterroot Bio

Harnessing the power of immunotherapy to discover and develop transformative medicines for patients with cardiovascular disease.

[Bitterroot Bio @BitterrootBio]

We're excited to present our latest anti-CD47 research data at AHA's Annual Scientific Sessions in New Orleans – check out our poster presentations on Nov 8th and 9th! #AHA2025 #cardioimmunology

[Bitterroot Bio @BitterrootBio]

Our team recently joined the BOLD AI Panel to discuss the transformative power of AI. At Bitterroot, we're not just observing this revolution—we're actively integrating AI into our core capabilities to accelerate our efforts, leading the charge in a rapidly evolving industry.

[Bitterroot Bio @BitterrootBio]

As we reflect on our recent progress, we celebrate the two-year anniversary marking our company’s launch and the rapid advancement of our atherosclerosis program from concept into Phase 2a trials!

[Bitterroot Bio @BitterrootBio]

On Global Running Day, we showed our unsinkable spirit! Every mile we ran turned into a donation to the American Heart Association, directly supporting ASCVD patients. Even small steps can lead to big changes in cardiovascular health! #ASCVD #Cardioimmunology #AHA

[Bitterroot Bio @BitterrootBio]

Read the full press release: https://t.co/YRYYAYZIxP

[Bitterroot Bio @BitterrootBio]

Exciting news!🎉The first patient has been dosed in our MATADOR Phase 2a clinical trial evaluating BRB-002, a novel immunomodulating therapy in development for ASCVD. BRB-002 directly targets the underlying plaque of ASCVD, offering a new potential treatment approach.

[Bitterroot Bio @BitterrootBio]

We will be at the Jefferies Global Healthcare Conference in New York City, where we will connect with industry leaders to share our vision for improving the lives of patients with cardiovascular disease. #cardioimmunology #ASCVD #JefferiesHealthcareConference

[Bitterroot Bio @BitterrootBio]

An encore display of our ACC poster detailing our BRB-002 Phase 1 results will be held at the Stanford Drug Discovery Symposium on April 28 & 29. Come check it out! #ASCVD #Cardioimmunology #AmericanCollegeofCardiology

[Bitterroot Bio @BitterrootBio]

Today, we presented foundational data from our Phase 1 study of BRB-002, a novel protein therapy in development for the treatment of ASCVD, demonstrating encouraging safety at all tested doses, with robust target engagement. #ACC25

View our poster: https://t.co/BC8JsMfZmK

[Bitterroot Bio @BitterrootBio]

It's not all pipettes and protocols! The Bitterroot team stepped out to enjoy the Stanford / Berkeley baseball game last Friday. Teamwork and heart are what drive us all forward!

[Bitterroot Bio @BitterrootBio]

Come see us present results from the Phase 1 study of BRB-002 at ACC’s Annual Scientific Session in Chicago! #ACC2025

[Bitterroot Bio @BitterrootBio]

We will be at the TD Cowen Health Care Conference in Boston, where our team will meet with industry leaders to discuss our efforts to improve the lives of patients with cardiovascular disease. Learn more about our science at https://t.co/2Db4XuFyx0 #cardioimmunology

[Bitterroot Bio @BitterrootBio]

Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers. Read the full Press Release here: https://t.co/cBbvc3ZinG

[Bitterroot Bio @BitterrootBio]

Thank you for the dedication of our talented Team and Partners. We look forward to a joyful season and a 2025 filled with heart, and transformative progress for cardiovascular patients everywhere. Cheers! #Bitterrootforward

[Bitterroot Bio @BitterrootBio]

Bitterroot Bio is excited to join academic, industry, regulatory, and cardiovascular patient representatives at the CVCT Forum this week in Washington, D.C.!
#CVCTForum #BitterrootBio

[Bitterroot Bio @BitterrootBio]

Bitterroot Bio will be at Evercore’s HealthCONx Conference on Dec. 3rd in Coral Gables. We are looking forward to connecting with industry leaders to help drive the future of cardiovascular care forward. #HealthCONx #HealthcareInnovation

[Bitterroot Bio @BitterrootBio]

We’re grateful to our team and our partners for their dedication and support as we advance our clinical studies in service of people suffering from atherosclerosis and cardiovascular disease. Wishing you a Thanksgiving holiday filled with gratitude. Happy Thanksgiving!

[Bitterroot Bio @BitterrootBio]

Our company leaders will be participating at the upcoming Jefferies London Healthcare Conference on November 20th and 21st. Looking forward to joining global healthcare leaders at one of the largest healthcare-dedicated conferences in Europe! #JefferiesHealthcare #BitterrootBio

[Bitterroot Bio @BitterrootBio]

Enrollment is complete for our Phase 1 study of BRB-002 in healthy volunteers. Topline findings are expected in early 2025, with our Phase 2 trial in patients with atherosclerosis to follow. All thanks to our participants, teams, and partners! Read more: https://t.co/ptX2BnhAEb

[Bitterroot Bio @BitterrootBio]

On Sept 24, our CMO Craig Basson, MD, PhD, will join a panel at the World Medical Innovation Forum #WMIF2024 to discuss “The Innovation Gap: Metabolic Drugs & Related Diseases.” Don’t miss insights from this exciting talk! #innovation #cardioimmunology